Candis Edwards is a distinguished pharmaceutical executive whose career reflects more than four decades of disciplined leadership, scientific insight, and unwavering dedication to public well-being. Throughout her journey, she has embodied a simple yet powerful guiding principle: “Integrity in Science, Excellence in Impact.” This belief has shaped every role she has undertaken, from her early scientific roots to her executive leadership overseeing regulatory affairs, compliance, and pharmacovigilance for some of the industry’s most influential organizations. Candis brings a rare blend of technical depth, strategic foresight, and global perspective, making her one of the most respected voices in pharmaceutical regulation and product stewardship.
Her career began at Pfizer Pharmaceuticals, where she cultivated her scientific foundation as an Associate Scientist. It was here that Candis learned the crucial balance between innovation and regulatory responsibility, contributing to projects that demanded precision, collaboration, and a deep respect for the scientific process. Those formative years allowed her to experience firsthand how meticulous development and thoughtful oversight ultimately protect patients. This early exposure fueled her interest in regulatory affairs and set the course for the leadership path she would later pursue.
Candis advanced into progressively senior roles throughout the 1990s and early 2000s, including serving as Vice President of Regulatory Affairs for Clay Park Labs, Perrigo, and the Wockhardt Research Centre. In these roles, she developed a reputation for transforming regulatory functions into strategic partners within the business, ensuring that compliance, product approvals, and cross-functional alignment became core pillars of organizational success. Her leadership during this period strengthened her ability to navigate complex international regulations, collaborate across scientific and corporate teams, and guide companies through evolving FDA expectations.
Her transition into executive leadership roles at Interpharm and ultimately Amneal Pharmaceuticals marked a defining chapter in her career. Over nearly 17 years with Amneal, Candis ascended to the role of Senior Vice President of Specialty Regulatory Affairs and Pharmacovigilance, a position in which she oversaw one of the industry’s most sensitive and mission-critical areas. She led regulatory strategy for specialty products, stewarded global compliance frameworks, and directed safety operations that ensured the well-being of millions of patients. Her capacity to lead teams through scientific, regulatory, and operational complexity showcased her unique ability to make clarity possible even in high-stakes environments.
Candis’ leadership at Amneal was shaped by her deep understanding of how regulatory and safety decisions influence long-term business viability. She worked closely with the FDA, managed intricate product submission pathways, and championed high-quality standards across the organization. Whether guiding a cross-functional team through a demanding approval cycle or shaping the company’s regulatory posture, Candis consistently demonstrated a solutions-oriented approach grounded in both technical expertise and human-centered leadership.
In 2025, Candis expanded her reach by founding Intentus Strategic Regulatory Consulting LLC, a firm dedicated to supporting pharmaceutical organizations and emerging life science startups. As CEO, she now uses her lifetime of experience to counsel companies seeking regulatory clarity, accelerated development timelines, and strategic guidance. Her advisory approach is grounded in practical wisdom, compassionate leadership, and an acute understanding of the pressures innovators face when bringing products to market.
A committed educator, Candis has also contributed significantly to academic and professional communities through university lecturing and ongoing mentorship. She has taught pharmaceutical engineering and regulatory affairs courses, helping shape the next generation of leaders who will carry the industry forward. Her involvement in global markets, particularly in Israel and India, has enriched her worldview and deepened her ability to collaborate across cultures, regulatory systems, and scientific disciplines.
Candis’ academic accomplishments include earning an MS in Industrial Pharmacy from St. John’s University and a BS in Bacteriology and Public Health from Wagner College. These academic foundations supported her lifelong pursuit of regulatory excellence and her ability to merge scientific understanding with executive leadership. Over the years, her expertise in areas such as FDA interactions, eCTD submissions, pharmacovigilance, and compliance frameworks has made her a trusted advisor within the pharmaceutical community.
Beyond her professional achievements, Candis is deeply committed to personal growth, social development, and holistic well-being. Yoga and meditation have long been part of her lifestyle, guiding her with balance and focus as she navigates the responsibilities of leadership. Her purpose today is grounded in service—giving back through mentorship, board participation, and advisory work that helps organizations innovate responsibly and sustainably.
Candis now seeks board service as a natural continuation of her commitment to advancing public health and supporting meaningful innovation. With more than 45 years of global experience, she brings unmatched insight into regulatory strategy, quality systems, and organizational governance. She considers herself a steward of integrity, a champion for compliance excellence, and a strategic partner capable of helping organizations build resilient pathways for future growth.
Character:
Candis demonstrates strong ethical leadership rooted in integrity, accountability, and compassion. She approaches challenges with humility and a steady resolve that instills trust across teams and organizations. Her commitment to doing what is right—scientifically and ethically—defines her character as a leader of unwavering credibility.
Knowledge:
Technical knowledge that spans every critical element of pharmaceutical regulation, clinical development, and product oversight, enabling her to guide organizations through complex compliance landscapes. She has mastered the intricacies of FDA engagement and global regulatory frameworks, always remaining adaptable to emerging standards. Her depth of understanding allows her to translate scientific and regulatory complexity into clear, actionable strategy.
Strategic:
Candis possesses the rare ability to blend analytical rigor with long-term vision, ensuring that regulatory decisions align with greater organizational goals. She anticipates industry shifts and prepares companies to navigate them with confidence and agility. Her strategic mindset empowers teams to innovate responsibly while safeguarding patient safety and compliance.
Communication:
Her communication style is clear, measured, and deeply collaborative, fostering alignment across scientific, legal, and executive stakeholders. She excels at translating technical concepts into messages that resonate with diverse audiences. Through teaching, team leadership, and advisory roles, she has developed a communication presence that inspires clarity, confidence, and shared purpose.
